Profiling the Skin Microbiome in Response to Altreno in Acne Patients

Completed · Phase 4

Conditions studied: Acne, Healthy

In brief

The study objective is to characterize the shift in the diversity and abundance of the skin microbial community at baseline and in response to Altreno monotherapy as compared to benzoyl peroxide (BPO) 2.5% leave-on gel monotherapy in acne patients.

Key facts

Study ID

NCT04548349

Run by

Beth Israel Deaconess Medical Center

People needed

25

Starts

2021-04-23

Expected to finish

2022-08-22

Last updated by the study team

2024-02-06

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A confirmed diagnosis of acne that warrants initiating topical medications.
• Denies use of any prescribed systemic acne treatments in the past 30 days.
• Denies use of any prescribed topical medications in the past 30 days.
• Denies use of any OTC topical acne medications in the past 14 days.
• Denies use of any emollients in the past 24 hours (if feasible).
• Denies bathing or facial washing in the past 12 hours (if feasible).
• Willingness to adhere to the recommended topical regimen during the duration of the study.

You may not qualify if…

• Women who are pregnant, breastfeeding, or planning to get pregnant during the study.
• Use of any investigational drug(s) in the past 3 months.

Where it is running

• Beth Israel Deacones Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.